TRITON-TIMI 38
2007
Trial to Assess Improvement in Therapeutic Outcomes
In 13,608 ACS patients undergoing planned PCI, prasugrel reduced ischaemic events but increased major bleeding relative to clopidogrel.
Result
Efficacy: CV death, non-fatal MI or non-fatal strokeHR 0.81
Below 1 favours prasugrel, above 1 favours clopidogrel.
- Absolute difference
- 2.2 points
The absolute difference is derived from the event rates.
Also reported: TIMI major bleed 2.4 % vs 1.8 %; fatal bleed higher with prasugrel.
- Subtopic
- Antiplatelets
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Wiviott SD, et al. N Engl J Med. 2007;357(20):2001-2015.doi 10.1056/NEJMoa0706482
Discussion & critique
Net harm in patients > 75 y, < 60 kg, or with prior stroke/TIA. These subgroups are contraindications. Selection of P2Y12 inhibitor remains a balance of ischaemic vs bleeding risk.